Company intelligence / Profile preview

Base Therapeutics

Shanghai (implied), Chinabeltandroadsummit.com ↗

Ownership: Private
Development stage: Phase 1

Overview

NK510, the world's first base-edited universal NK cell product, received IND approvals in both China and the United States in 2024. Multiple Investigator Initiated Trials (IITs) for NK510 and NK520 have been conducted, with preliminary safety and efficacy for solid tumors confirmed[7][6].

Therapeutic areas: OncologyImmunologyRare Diseases
Modalities: Gene editingCell therapyBase editingNK cell therapyCAR-T cell therapyIn vivo gene therapy
Industry: Biotech

Drug pipeline

6 assets

NK510

5 more assets in the full pipeline.

Request access →

Partnerships

Licensed AccuBase® technology to a leading international CAR-T cell therapy companycollaborates with agricultural enterprises for thornless fish developmentpartnerships with other biopharmaceutical companies for cell product development[6][8]

Beyond the preview

Go deeper on Base Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Base Therapeutics.

Explore the full profile